Advertisement

Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington’s Disease

  • Brijesh Kumar Singh
  • Naman Vatsa
  • Vinod K. Nelson
  • Vipendra Kumar
  • Shashi Shekhar Kumar
  • Subhash C. Mandal
  • Mahadeb Pal
  • Nihar Ranjan Jana
Article

Abstract

Huntington’s disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by expansion of CAG repeats in the coding area of huntingtin gene. In the HD brain, mutant huntingtin protein goes through proteolysis, and its amino-terminal portion consisting of polyglutamine repeats accumulate as inclusions that result in progressive impairment of cellular protein quality control system. Here, we demonstrate that partial rescue of the defective protein quality control in HD model mouse by azadiradione (a bioactive limonoids found in the seed of Azadirachta indica) could potentially improve the disease pathology. Prolonged treatment of azadiradione to HD mice significantly improved the progressive deterioration in body weight, motor functioning along with extension of lifespan. Azadiradione-treated HD mice brain also exhibited considerable decrease in mutant huntingtin aggregates load and improvement of striatal pathology in comparison with age-matched saline-treated HD controls. Biochemical analysis further revealed upregulation and activation of not only HSF1 (master regulator of protein folding) but also Ube3a (an ubiquitin ligase involved in the clearance of mutant huntingtin) in azadiradione-treated mice. Our results indicate that azadiradione-mediated enhanced folding and clearance of mutant huntingtin might underlie improved disease pathology in HD mice and suggests that it could be a potential therapeutic molecule to delay the progression of HD.

Keywords

Huntington’s disease Azadiradione HSF1 Ube3a Proteostasis 

Notes

Acknowledgements

The authors would like to sincerely thank Mr. Ankit Sharma and Mr. Mahendra Kumar Singh for their technical support.

Funding Information

This work was supported by the core funding of the National Brain Research Centre (under Department of Biotechnology, Government of India). NRJ is a recipient of TATA Innovation Fellowship from Department of Biotechnology, Government of India (BT/HRD/35/01/03/2013).

Compliance with Ethical Standards

All experiments were conducted according to the strict guideline proposed by the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment and Forestry, Government of India and were approved by the Institutional Animal Ethics Committee of the National Brain Research Centre (Protocol number NBRC/IAEC/2017/120).

References

  1. 1.
    Mendez MF (1994) Huntington’s disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med 24(3):189–208.  https://doi.org/10.2190/HU6W-3K7Q-NAEL-XU6KCrossRefPubMedGoogle Scholar
  2. 2.
    Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44(6):559–577.  https://doi.org/10.1097/00005072-198511000-00003CrossRefPubMedGoogle Scholar
  3. 3.
    Hedreen JC, Folstein SE (1995) Early loss of neostriatal striosome neurons in Huntington’s disease. J Neuropathol Exp Neurol 54(1):105–120.  https://doi.org/10.1097/00005072-199501000-00013CrossRefPubMedGoogle Scholar
  4. 4.
    Graveland GA, Williams RS, DiFiglia M (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington’s disease. Science 227(4688):770–773.  https://doi.org/10.1126/science.3155875CrossRefPubMedGoogle Scholar
  5. 5.
    The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72(6):971–983.  https://doi.org/10.1016/0092-8674(93)90585-E
  6. 6.
    Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, Bromm M, Kazemi-Esfarjani P et al (1996) Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat Genet 13(4):442–449.  https://doi.org/10.1038/ng0896-442CrossRefPubMedGoogle Scholar
  7. 7.
    Landles C, Bates GP (2004) Huntingtin and the molecular pathogenesis of Huntington’s disease. Fourth in molecular medicine review series. EMBO Rep 5(10):958–963.  https://doi.org/10.1038/sj.embor.7400250CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Jones L, Hughes A (2011) Pathogenic mechanisms in Huntington’s disease. Int Rev Neurobiol 98:373–418.  https://doi.org/10.1016/B978-0-12-381328-2.00015-8CrossRefPubMedGoogle Scholar
  9. 9.
    DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277(5334):1990–1993.  https://doi.org/10.1126/science.277.5334.1990CrossRefPubMedGoogle Scholar
  10. 10.
    Orr HT, Zoghbi HY (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30(1):575–621.  https://doi.org/10.1146/annurev.neuro.29.051605.113042CrossRefPubMedGoogle Scholar
  11. 11.
    Gatchel JR, Zoghbi HY (2005) Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 6(10):743–755.  https://doi.org/10.1038/nrg1691CrossRefPubMedGoogle Scholar
  12. 12.
    Margulis J, Finkbeiner S (2014) Proteostasis in striatal cells and selective neurodegeneration in Huntington’s disease. Front Cell Neurosci 8:218CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Rubinsztein DC, Carmichael J (2003) Huntington’s disease: molecular basis of neurodegeneration. Expert Rev Mol Med 5(20):1–21.  https://doi.org/10.1017/S1462399403006549CrossRefPubMedGoogle Scholar
  14. 14.
    Jana NR, Nukina N (2003) Recent advances in understanding the pathogenesis of polyglutamine diseases: involvement of molecular chaperones and ubiquitin-proteasome pathway. J Chem Neuroanat 26(2):95–101.  https://doi.org/10.1016/S0891-0618(03)00029-2CrossRefPubMedGoogle Scholar
  15. 15.
    Sarkar S, Rubinsztein DC (2008) Huntington’s disease: degradation of mutant huntingtin by autophagy. FEBS J 275(17):4263–4270.  https://doi.org/10.1111/j.1742-4658.2008.06562.xCrossRefPubMedGoogle Scholar
  16. 16.
    Wang J, Wang CE, Orr A, Tydlacka S, Li SH, Li XJ (2008) Impaired ubiquitin-proteasome system activity in the synapses of Huntington’s disease mice. J Cell Biol 180(6):1177–1189.  https://doi.org/10.1083/jcb.200709080CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Jana NR, Zemskov EA, Wang G, Nukina N (2001) Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10(10):1049–1059.  https://doi.org/10.1093/hmg/10.10.1049CrossRefPubMedGoogle Scholar
  18. 18.
    Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H et al (2007) Global changes to the ubiquitin system in Huntington’s disease. Nature 448(7154):704–708.  https://doi.org/10.1038/nature06022CrossRefPubMedGoogle Scholar
  19. 19.
    Cortes CJ, La Spada AR (2014) The many faces of autophagy dysfunction in Huntington’s disease: from mechanism to therapy. Drug Discov Today 19(7):963–971.  https://doi.org/10.1016/j.drudis.2014.02.014CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Valera AG, Diaz-Hernandez M, Hernandez F, Ortega Z, Lucas JJ (2005) The ubiquitin-proteasome system in Huntington’s disease. Neuroscientist 11(6):583–594.  https://doi.org/10.1177/1073858405280639CrossRefPubMedGoogle Scholar
  21. 21.
    Alavez S, Vantipalli MC, Zucker DJ, Klang IM, Lithgow GJ (2011) Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature 472(7342):226–229.  https://doi.org/10.1038/nature09873CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Sands WA, Page MM, Selman C (2017) Proteostasis and ageing: insights from long-lived mutant mice. J Physiol 595(20):6383–6390.  https://doi.org/10.1113/JP274334CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Rajalingam K, Dikic I (2011) Healthy ageing through regulated proteostasis. EMBO J 30(15):2983–2985.  https://doi.org/10.1038/emboj.2011.237CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Rubinsztein DC (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443(7113):780–786.  https://doi.org/10.1038/nature05291CrossRefPubMedGoogle Scholar
  25. 25.
    Maheshwari M, Bhutani S, Das A, Mukherjee R, Sharma A, Kino Y, Nukina N, Jana NR (2014) Dexamethasone induces heat shock response and slows down disease progression in mouse and fly models of Huntington’s disease. Hum Mol Genet 23(10):2737–2751.  https://doi.org/10.1093/hmg/ddt667CrossRefPubMedGoogle Scholar
  26. 26.
    Fujimoto M, Takaki E, Hayashi T, Kitaura Y, Tanaka Y, Inouye S, Nakai A (2005) Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models. J Biol Chem 280(41):34908–34916.  https://doi.org/10.1074/jbc.M506288200CrossRefPubMedGoogle Scholar
  27. 27.
    Chafekar SM, Duennwald ML (2012) Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin. PLoS One 7(5):e37929.  https://doi.org/10.1371/journal.pone.0037929CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Gomez-Pastor R, Burchfiel ET, Neef DW, Jaeger AM, Cabiscol E, McKinstry SU, Doss A, Aballay A et al (2017) Abnormal degradation of the neuronal stress-protective transcription factor HSF1 in Huntington’s disease. Nat Commun 8:14405.  https://doi.org/10.1038/ncomms14405CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Neef DW, Jaeger AM, Thiele DJ (2011) Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases. Nat Rev Drug Discov 10(12):930–944.  https://doi.org/10.1038/nrd3453CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC (2009) Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ 16(1):46–56.  https://doi.org/10.1038/cdd.2008.110CrossRefPubMedGoogle Scholar
  31. 31.
    Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF et al (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36(6):585–595.  https://doi.org/10.1038/ng1362CrossRefPubMedGoogle Scholar
  32. 32.
    Tsai YC, Fishman PS, Thakor NV, Oyler GA (2003) Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem 278(24):22044–22055.  https://doi.org/10.1074/jbc.M212235200CrossRefPubMedGoogle Scholar
  33. 33.
    Miller VM, Nelson RF, Gouvion CM, Williams A, Rodriguez-Lebron E, Harper SQ, Davidson BL, Rebagliati MR et al (2005) CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci 25(40):9152–9161.  https://doi.org/10.1523/JNEUROSCI.3001-05.2005CrossRefPubMedGoogle Scholar
  34. 34.
    Jana NR, Dikshit P, Goswami A, Kotliarova S, Murata S, Tanaka K, Nukina N (2005) Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J Biol Chem 280(12):11635–11640.  https://doi.org/10.1074/jbc.M412042200CrossRefPubMedGoogle Scholar
  35. 35.
    Bhat KP, Yan S, Wang CE, Li S, Li XJ (2014) Differential ubiquitination and degradation of huntingtin fragments modulated by ubiquitin-protein ligase E3A. Proc Natl Acad Sci U S A 111(15):5706–5711.  https://doi.org/10.1073/pnas.1402215111CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Mishra A, Dikshit P, Purkayastha S, Sharma J, Nukina N, Jana NR (2008) E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation and suppresses polyglutamine protein aggregation and toxicity. J Biol Chem 283(12):7648–7656.  https://doi.org/10.1074/jbc.M706620200CrossRefPubMedGoogle Scholar
  37. 37.
    Yang H, Zhong X, Ballar P, Luo S, Shen Y, Rubinsztein DC, Monteiro MJ, Fang S (2007) Ubiquitin ligase Hrd1 enhances the degradation and suppresses the toxicity of polyglutamine-expanded huntingtin. Exp Cell Res 313(3):538–550.  https://doi.org/10.1016/j.yexcr.2006.10.031CrossRefPubMedGoogle Scholar
  38. 38.
    Sugiura A, Yonashiro R, Fukuda T, Matsushita N, Nagashima S, Inatome R, Yanagi S (2011) A mitochondrial ubiquitin ligase MITOL controls cell toxicity of polyglutamine-expanded protein. Mitochondrion 11(1):139–146.  https://doi.org/10.1016/j.mito.2010.09.001CrossRefPubMedGoogle Scholar
  39. 39.
    Nelson VK, Ali A, Dutta N, Ghosh S, Jana M, Ganguli A, Komarov A, Paul S et al (2016) Azadiradione ameliorates polyglutamine expansion disease in Drosophila by potentiating DNA binding activity of heat shock factor 1. Oncotarget 7(48):78281–78296.  https://doi.org/10.18632/oncotarget.12930PubMedPubMedCentralGoogle Scholar
  40. 40.
    Subapriya R, Nagini S (2005) Medicinal properties of neem leaves: a review. Curr Med Chem Anticancer Agents 5(2):149–146.  https://doi.org/10.2174/1568011053174828CrossRefPubMedGoogle Scholar
  41. 41.
    Kumar VS, Navaratnam V (2013) Neem (Azadirachta indica): prehistory to contemporary medicinal uses to humankind. Asian Pac J Trop Biomed 3(7):505–514.  https://doi.org/10.1016/S2221-1691(13)60105-7CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Greer PL, Hanayama R, Bloodgood BL, Mardinly AR, Lipton DM, Flavell SW, Kim TK, Griffith EC et al (2010) The Angelman syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell 140(5):704–716.  https://doi.org/10.1016/j.cell.2010.01.026CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Mishra A, Godavarthi SK, Maheshwari M, Goswami A, Jana NR (2009) The ubiquitin ligase E6-AP is induced and recruited to aggresomes in response to proteasome inhibition and may be involved in the ubiquitination of Hsp70-bound misfolded proteins. J Biol Chem 284(16):10537–10545.  https://doi.org/10.1074/jbc.M806804200CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y et al (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87(3):493–506.  https://doi.org/10.1016/S0092-8674(00)81369-0CrossRefPubMedGoogle Scholar
  45. 45.
    Maheshwari M, Shekhar S, Singh BK, Jamal I, Vatsa N, Kumar V, Sharma A, Jana NR (2014) Deficiency of Ube3a in Huntington’s disease mice brain increases aggregate load and accelerates disease pathology. Hum Mol Genet 23(23):6235–6245.  https://doi.org/10.1093/hmg/ddu343CrossRefPubMedGoogle Scholar
  46. 46.
    Ilango K, Maharajan G, Narasimhan S (2013) Anti-nociceptive and anti-inflammatory activities of Azadirachta indica fruit skin extract and its isolated constituent azadiradione. Nat Prod Res 27(16):1463–1467.  https://doi.org/10.1080/14786419.2012.717288CrossRefPubMedGoogle Scholar
  47. 47.
    Singh R, Mishra V, Pandeti S, Palit G, Barthwal MK, Pandey HP, Narender T (2015) Cytoprotective and anti-secretory effects of Azadiradione isolated from the seeds of Azadirachta indica (neem) on gastric ulcers in rat models. Phytother Res 29(6):910–916.  https://doi.org/10.1002/ptr.5332CrossRefPubMedGoogle Scholar
  48. 48.
    Bibb JA, Yan Z, Svenningsson P, Snyder GL, Pieribone VA, Horiuchi A, Nairn AC, Messer A et al (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington’s disease mice. Proc Natl Acad Sci U S A 97(12):6809–6814.  https://doi.org/10.1073/pnas.120166397CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Maheshwari M, Samanta A, Godavarthi SK, Mukherjee R, Jana NR (2012) Dysfunction of the ubiquitin ligase Ube3a may be associated with synaptic pathophysiology in a mouse model of Huntington disease. J Biol Chem 287(35):29949–29957.  https://doi.org/10.1074/jbc.M112.371724CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Sittler A, Lurz R, Lueder G, Priller J, Lehrach H, Hayer-Hartl MK, Hartl FU, Wanker EE (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington’s disease. Hum Mol Genet 10(12):1307–1315.  https://doi.org/10.1093/hmg/10.12.1307CrossRefPubMedGoogle Scholar
  51. 51.
    Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, Toda T (2008) Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J Biol Chem 283(38):26188–26197.  https://doi.org/10.1074/jbc.M710521200CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Labbadia J, Cunliffe H, Weiss A, Katsyuba E, Sathasivam K, Seredenina T, Woodman B, Moussaoui S et al (2011) Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J Clin Invest 121(8):3306–3319.  https://doi.org/10.1172/JCI57413CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Westerheide SD, Bosman JD, Mbadugha BN, Kawahara TL, Matsumoto G, Kim S, Gu W, Devlin JP et al (2004) Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 279(53):56053–56060.  https://doi.org/10.1074/jbc.M409267200CrossRefPubMedGoogle Scholar
  54. 54.
    Sundar SV, Li YY, Rollwagen FM, Maheshwari RK (2005) Hemorrhagic shock induces differential gene expression and apoptosis in mouse liver. Biochem Biophys Res Commun 332(3):688–696.  https://doi.org/10.1016/j.bbrc.2005.05.008CrossRefPubMedGoogle Scholar
  55. 55.
    Sonna LA, Hawkins L, Lissauer ME, Maldeis P, Towns M, Johnson SB, Moore R, Singh IS et al (2010) Core temperature correlates with expression of selected stress and immunomodulatory genes in febrile patients with sepsis and noninfectious SIRS. Cell Stress Chaperones 15(1):55–66.  https://doi.org/10.1007/s12192-009-0121-1CrossRefPubMedGoogle Scholar
  56. 56.
    Xue H, Slavov D, Wischmeyer PE (2012) Glutamine-mediated dual regulation of heat shock transcription factor-1 activation and expression. J Biol Chem 287(48):40400–40413.  https://doi.org/10.1074/jbc.M112.410712CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Smith R, Brundin P, Li JY (2005) Synaptic dysfunction in Huntington’s disease: a new perspective. Cell Mol Life Sci 62(17):1901–1912.  https://doi.org/10.1007/s00018-005-5084-5CrossRefPubMedGoogle Scholar
  58. 58.
    Sepers MD, Raymond LA (2014) Mechanisms of synaptic dysfunction and excitotoxicity in Huntington’s disease. Drug Discov Today 19(7):990–996.  https://doi.org/10.1016/j.drudis.2014.02.006CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  • Brijesh Kumar Singh
    • 1
  • Naman Vatsa
    • 1
  • Vinod K. Nelson
    • 2
  • Vipendra Kumar
    • 1
  • Shashi Shekhar Kumar
    • 1
  • Subhash C. Mandal
    • 2
  • Mahadeb Pal
    • 3
  • Nihar Ranjan Jana
    • 1
  1. 1.Cellular and Molecular Neuroscience LaboratoryNational Brain Research CentreGurgaonIndia
  2. 2.Division of Pharmacognosy, Department of Pharmaceutical TechnologyJadavpur UniversityKolkataIndia
  3. 3.Division of Molecular MedicineBose InstituteKolkataIndia

Personalised recommendations